Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report

Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents...

Full description

Bibliographic Details
Main Authors: Wolowacz, S., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., Lloyd, A., Norman, Richard
Format: Journal Article
Published: Elsevier Inc. 2016
Online Access:http://hdl.handle.net/20.500.11937/38646
_version_ 1848755376934092800
author Wolowacz, S.
Briggs, A.
Belozeroff, V.
Clarke, P.
Doward, L.
Goeree, R.
Lloyd, A.
Norman, Richard
author_facet Wolowacz, S.
Briggs, A.
Belozeroff, V.
Clarke, P.
Doward, L.
Goeree, R.
Lloyd, A.
Norman, Richard
author_sort Wolowacz, S.
building Curtin Institutional Repository
collection Online Access
description Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data. However, trials designed primarily to evaluate efficacy and safety often present challenges to the optimal collection of HSU estimates for economic models. Careful planning is needed to determine which of the HSU estimates may be measured in planned trials; to establish the optimal methodology; and to plan any additional studies needed. This report aimed to provide a framework for researchers to plan the collection of health-utility data in clinical studies to provide high-quality HSU estimates for economic modeling. Recommendations are made for early planning of health-utility data collection within a research and development program; design of health-utility data collection during protocol development for a planned clinical trial; design of prospective and cross-sectional observational studies and alternative study types; and statistical analyses and reporting.
first_indexed 2025-11-14T08:55:20Z
format Journal Article
id curtin-20.500.11937-38646
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:55:20Z
publishDate 2016
publisher Elsevier Inc.
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-386462017-09-13T14:18:22Z Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report Wolowacz, S. Briggs, A. Belozeroff, V. Clarke, P. Doward, L. Goeree, R. Lloyd, A. Norman, Richard Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data. However, trials designed primarily to evaluate efficacy and safety often present challenges to the optimal collection of HSU estimates for economic models. Careful planning is needed to determine which of the HSU estimates may be measured in planned trials; to establish the optimal methodology; and to plan any additional studies needed. This report aimed to provide a framework for researchers to plan the collection of health-utility data in clinical studies to provide high-quality HSU estimates for economic modeling. Recommendations are made for early planning of health-utility data collection within a research and development program; design of health-utility data collection during protocol development for a planned clinical trial; design of prospective and cross-sectional observational studies and alternative study types; and statistical analyses and reporting. 2016 Journal Article http://hdl.handle.net/20.500.11937/38646 10.1016/j.jval.2016.06.001 Elsevier Inc. restricted
spellingShingle Wolowacz, S.
Briggs, A.
Belozeroff, V.
Clarke, P.
Doward, L.
Goeree, R.
Lloyd, A.
Norman, Richard
Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report
title Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report
title_full Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report
title_fullStr Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report
title_full_unstemmed Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report
title_short Estimating Health-State Utility for Economic Models in Clinical Studies: an ISPOR Good Research Practices Task Force Report
title_sort estimating health-state utility for economic models in clinical studies: an ispor good research practices task force report
url http://hdl.handle.net/20.500.11937/38646